206 results
8-K
EX-99.1
WINT
Windtree Therapeutics Inc
4 Nov 04
Entry into a Material Definitive Agreement
12:00am
of chronic lung disease. These respiratory conditions are cited as some of
the most significant unmet medical needs for the neonatal … been challenged with means to adequately treat an array of other
respiratory problems that beset fragile premature infants. These include chronic
8-K
EX-99.1
WINT
Windtree Therapeutics Inc
16 Jun 06
Discovery Labs’ SurfaxinÒ Granted Orphan Drug Designation for the Prevention of Bronchopulmonary Dysplasia
12:00am
, also known as Chronic Lung Disease) in premature infants. Surfaxin, a precision-engineered lung surfactant replacement therapy, has previously … cause chronic injury and scarring of the lungs - resulting in BPD.
The U.S. Orphan Drug Act is intended to assist and encourage companies to develop
8-K
EX-99.1
WINT
Windtree Therapeutics Inc
4 Dec 07
Discovery Labs’ Aerosurf™ Improves Lung Function and Reduces Inflammation in a Model of Respiratory Distress Syndrome
12:00am
associated with lung injury and chronic lung disease.
Aerosurf is an aerosolized formulation of Discovery Lab’s novel KL4 surfactant technology … subsequently developing chronic lung disease. The neonatal, pediatric, and adult critical care medical communities recognize the potential
8-K
EX-99.1
WINT
Windtree Therapeutics Inc
30 Jan 06
Other Events
12:00am
Track designation to Discovery’s lead product, Surfaxin®, for the prevention and treatment of Bronchopulmonary Dysplasia (BPD, also known as Chronic … of mechanical ventilation may cause chronic injury and scarring of the lungs - resulting in BPD.
Robert J. Capetola, Ph.D., President and Chief Executive
8-K
WINT
Windtree Therapeutics Inc
7 Mar 00
Current Report on Form 8-K
12:00am
), into aerosolized
forms for the potential therapy of asthma, chronic obstructive pulmonary disease
(COPD), acute and chronic bronchitis
8-K
EX-99.1
rmra4c an6gn3
3 Nov 05
Discovery Labs’ Reports Third Quarter 2005 Financial Results and Business Progress
12:00am
8-K
EX-1
13llhd
26 Feb 03
Other events
12:00am
8-K
EX-99.1
9ex8tryc9s
1 Mar 06
Discovery Labs Reports Fourth Quarter 2005 Financial Results
12:00am
8-K
kma ncjgmtdk
5 Jun 03
Other events
12:00am
8-K
m101j62e
15 Oct 99
Current Report
12:00am
8-K
EX-99.1
gk8 a3xnv
9 Dec 04
Entry into a Material Definitive Agreement
12:00am
8-K
EX-99.3
43ev9nc yfa
8 May 08
Discovery Labs Reports First Quarter 2008 Financial Results
12:00am
8-K
EX-99.1
d4zpod508pj1 1810v7
3 Jan 06
Represents strategic decision to control manufacturing of Surfaxinâ and SRT pipeline
12:00am
8-K
EX-99.1
oyerp2 ulxs
21 May 03
Financial statements and exhibits
12:00am
8-K
EX-99.1
scstrtw
12 Dec 05
Entry into a Material Definitive Agreement
12:00am
8-K
ht63ysq5izsxshhakway
16 Jun 06
Discovery Labs’ SurfaxinÒ Granted Orphan Drug Designation for the Prevention of Bronchopulmonary Dysplasia
12:00am
8-K
enw vfz44af
4 Dec 07
Discovery Labs’ Aerosurf™ Improves Lung Function and Reduces Inflammation in a Model of Respiratory Distress Syndrome
12:00am
8-K
8nv3ywbzodxk u3j8ai
22 Mar 21
Entry into a Material Definitive Agreement
3:54pm